Yazdanbakhsh Karina
Complement Biology, New York Blood Center, New York, NY 10021, USA.
Transfusion. 2005 Aug;45(2 Suppl):122S-9S. doi: 10.1111/j.1537-2995.2005.00526.x.
A major objective of my National Blood Foundation (NBF)-funded proposal was to produce recombinant soluble forms of a complement regulatory protein called complement receptor 1 (CR1) that carries the Knops blood group system antigens to perform antibody neutralization studies. By generating these recombinant proteins, we were able to inhibit several Knops antibodies in patient serum samples, thereby demonstrating their usefulness for clinical use. Interestingly, the recombinant CR1 proteins generated through NBF funding were also found to strongly reduce complement-mediated red cell destruction in a mouse hemolytic transfusion model. In this review, I will outline our NBF-funded studies, give an overview of recent advances from our group and others in the development of complement therapeutics, and highlight their potential use in the transfusion medicine setting.
我由国家血液基金会（NBF）资助的研究项目的一个主要目标是生产一种名为补体受体1（CR1）的补体调节蛋白的重组可溶性形式，该蛋白携带诺普斯血型系统抗原，用于进行抗体中和研究。通过生成这些重组蛋白，我们能够抑制患者血清样本中的几种诺普斯抗体，从而证明它们在临床应用中的有效性。有趣的是，通过NBF资助产生的重组CR1蛋白在小鼠溶血性输血模型中也被发现能强烈减少补体介导的红细胞破坏。在这篇综述中，我将概述我们由NBF资助的研究，综述我们团队以及其他团队在补体疗法开发方面的最新进展，并强调它们在输血医学领域的潜在用途。
